Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 12 / 12 / 2019

Welcome to JCTH

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy

ORIGINAL ARTICLE

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy

Nikhil Kapila1, Kawtar Al Khalloufi2, Gianina Flocco3, K.V. Narayanan Menon3, Christina Lindenmeyer3, Diego Reino2, Jason M. Vanatta2, Samer Ebaid2, Andreas Tzakis2 and Xaralambos Bobby Zervos*,2

1Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, USA
2Department of Transplant, Cleveland Clinic Florida, Weston, FL, USA
3Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA
*Correspondence to: Xaralambos Bobby Zervos, Department of Transplant, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA. Tel: +1-954-659-5133, Fax: +1-954-659-6731, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2019;7(2):122-126 DOI: 10.14218/JCTH.2019.00014
Received: March 27, 2019 Accepted: May 15, 2019 Published online: June 4, 2019

Abstract

Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor.

Methods: We conducted a retrospective study, including patients seen from July 2015 to April 2017. HCV viremic patients transplanted with a liver from a HCV viremic donor and subsequently treated with DAAs were included. Outcomes assessed included undetectable viral load at 12 weeks after completing DAA therapy (sustained virologic response, SVR12), adverse events, and interactions with immunosuppression.

Results: Twenty-four HCV viremic recipients received livers from HCV viremic donors. Median age was 63 years, and the majority (79.2%) were genotype 1a. Donors and recipients were viremic at the time of transplant. Median modified model for end-stage liver disease score was 19, and median time on the waitlist was 81 days. Median time from transplant to initiation of DAA therapy was 123 days. Several DAA regimens were used and 15 (62.5%) patients did not receive ribavirin. Treatment duration ranged from 12 to 24 weeks. Twenty-three (95.8%) patients achieved SVR12. Five (20.8%) patients developed adverse events; however, none required DAA discontinuation.

Conclusions: DAA therapy was efficacious and well tolerated in HCV viremic recipients who underwent liver transplantation from a HCV viremic donor.

Keywords

Hepatitis C, Direct-acting antiviral agents, Donor pool expansion, High risk donors, Liver transplantation

 

 

 

 

Journal of Clinical and Translational Hepatology 2019 vol. 7, 122-126  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home Vol 7 Issue 2 Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy